Thank you, Charlie.
team for Cushing's that with patients yet built Leading believe solid there foundation, considerably patients that is to interest an more medication there of it. a by patients a than on and are is syndrome Korlym patients with many a Cushing's was receive business first. once puts Cushing's endocrinologists Our syndrome excellent increasingly life-saving eligible promoted have the assumed. syndrome are treatment who commercial
extremely potential syndrome the optimistic and Cushing's patients. and making business the substantial growth are to are of We investments treatment these about our screening of improve
providing of XXXX to guidance We revenue million. are $XXX million $XXX
development clinical selective In our and generating significantly proprietary we cash dazucorilant XXXX, relacorilant, modulators, programs addition to substantial cortisol advanced miricorilant. of the in
of platinum-resistant progress to expect further X of dazucorilant trial Phase syndrome submission Phase with Phase in X ovarian We of miricorilant in cancer, and next XX confirmatory Cushing's of X the our and enrollment NDA of trial months relacorilant's the make in in trial relacorilant NASH. ALS, in
the have be development many in hypothesis can and powerful research upon our mechanism modulation a inception, efforts cortisol built therapeutic disorders. serious Since the
They by receptor, our off-target Korlym's, effects serious the receptor, binding product's, approved not do don't modulate some the it glucocorticoid cortisol's so GR. of effects. or compounds most to proprietary bind cause Our progesterone to
cortisol's progesterone's are activity Interestingly, while not they modulate compounds identical. activity, without our modulating
Some cross do the not. barrier, blood-brain others
of potent Some metabolic perform best in disease. models others more of models solid tumors, are in
diverse be of These variety to allow wide others disorders. a global study effects. us more to Some qualities appear tissue-specific, have
and Cushing's are of ALS, syndrome. ovarian, NASH we programs prostate conducting Currently, and, course, cancer, adrenal in
have and are We modulation's investigating role other clinical in diseases and cortisol in preclinical development. additional compounds
has business Cushing's continue will funded so. activities all Our to do of these and syndrome
PR-related is it competing the effect a cortisol pregnancy, you patients not hypercortisolism selective Relacorilant bleeding. side low Korlym, effect including its of GRADIENT. of evaluating cause in relacorilant effects, discontinuation. it cortisol relacorilant for not the By for and endometrial serious does cause two to does and short, treatment in at is modulator. different does potassium, experienced receptor. GRACE most receptor, a hypokalemia, progesterone we bind are trials: by XX% mechanism, cause with Like X pivotal Korlym's by of Unlike of a the glucocorticoid termination leading and to a also thickening Korlym, Korlym-induced side vaginal appear not PR As Phase know, so of achieves trial. hypokalemia Korlym
Cushing's control, no endometrial relacorilant-induced Phase in trial variety symptoms drug-induced XXXX. Patients The in thickening hypokalemia. vaginal experienced data bleeding well There instances as compelling. meaningful and and in Frontiers Endocrinology and Relacorilant's of syndrome. a or efficacy were safety were published of in hypertension X signs and glucose July of as in were results improvements no other
pleased in that to announce weeks. the trial are coming GRACE complete that We believe we we have to our enrollment in patients enough screening and
as serve basis of to NDA submission GRACE submit in we expect the which We first the XXXX. our quarter Cushing's syndrome, to for in plan
trial poor. etiology decline, experience Our effects caused but by whose hypercortisolism, in in outcomes their studying this are relacorilant's adrenal syndrome a patients adenoma Cushing's Patients GRADIENT, second Cushing's with an less often or hyperplasia. is of rapid Phase X adrenal health syndrome is
these we on we data GRADIENT, not depend patients. in While findings do its syndrome our expect will expect to that do care from NDA improve Cushing's of the
in to Finally, a Phase X randomized quarter. Korlym study double-blind placebo-controlled this initiate we plan
diabetologists CATALYST determined complete of is the will helped to in the in to and have patients Korlym. which treat study the examine We named of prominent most type expect prevalence enrollment are control patients study. year. in by hypercortisolism patients, have difficult we design X participating this and X,XXX CATALYST. with hypercortisolism country diabetes with the to end this the Planned The
in of later mechanism the by increasing that prominent confirmed is program investigators apoptosis. three beneficial and researchers. is oncology postulated effect testing by chemotherapy against the Chicago mechanisms the apoptosis, Our chemotherapy cell is solid tumors. by first One works to of anti-cancer meant Cortisol suppressing programmed other death at induce University
cancer, selective Relacorilant effect benefit enhanced provided of addition of by our successful in with modulator, women many Phase meaningful likely blending ovarian X cortisol's to women study. cortisol trial In the controlled a effect. relacorilant, anti-apoptotic our platinum-resistant chemotherapy, of the the in
While the appeared including taxanes, more some these beneficial in effects on had previous previous lines women's resensitize chemotherapy's relacorilant or to progressed two disease to disease women. of treatment,
relacorilant survival group and the progression-free before, after the day day received monotherapy. the with of improvement the Those longer arm, comparator compared intermittent those of significant significance. in relacorilant in the they than approached who and response in day statistically duration a that to Women intermittently, nab-paclitaxel, also statistical live received received the exhibited p-value nab-paclitaxel who a group
received alive are that patients alone. XX% date the to indicates relacorilant three after the to who to experienced who who alone. study analysis intermittent nab-paclitaxel alive years received years nab-paclitaxel more Our took were Perhaps those even patients after compared of who study XX% nab-paclitaxel of start who intermittent start burden relacorilant plus took took versus none relacorilant additional no compared only two important, who nab-paclitaxel took alone. XX% side effect women
and The the Clinical Meeting. results for Medical of at the Annual XXXX European were in XXXX meetings, presentations Society XXXX from podium ESMO, at study and Society the Oncology, Oncology, featured American ASCO,
key ROSELLA's cancer, our either and plus XXX survival ROSELLA, enrolling or primary overall women, enrollment with alone. secondary study receive in tracks survival is our platinum-resistant will progression-free The X randomized active design relacorilant endpoint. ovarian planned trial a X one-to-one patients. with Phase nab-paclitaxel to Phase nab-paclitaxel pivotal of endpoint be closely
are United the of and collaboration Europe. leading Group conducting clinicians Network States groups Trial We the the in study with from Oncology the Oncology in European in Gynecologic Gynecological
has our Our effect standard to to view, have goal care improved important this would that side gynecological without advance, women in in simply replicate relacorilant's nab-paclitaxel is relacorilant oncologists Phase results. Phase a and potential with survival X constitute new an plus medical X benefit, potential positive cancer. increased of become in ovarian platinum-resistant told burden, Leading the their
cancer experience enzalutamide, of modulation may by by prescribed to is pathway. activity useful cortisol patients why an treated a reason resurgent prove Deprived switch A is major disease. growth. second growth stimulate prostate stimulation, antagonist, androgen Cortisol the widely mechanism tumor to which androgen with stimulation eventually their cortisol important receptor with blocking tumor
have a prostate Our patients cortisol an enzalutamide trial collaborators deprivation androgen adding these a of close midyear, to had relacorilant X with initial our hypothesis Phase at plus begin therapy this before University to will route. prostatectomy. placebo-controlled randomized modulator patients escape By is Chicago cancer in of tumor plan the that
intended therapeutic body's blunt which immune mechanism A of cancer the therapies tumors cortisol by immune the system. treat of immune -- seeks the effectiveness third suppresses the response. enhancing Cortisol stimulate system, to may to
inhibitors, Our therapies. hypothesis as enhance checkpoint effectiveness may cortisol a adding the such modulator to is immunotherapies, of that these
Merck's tumors whose produce checkpoint cancer advanced conducting excess trial plus drug are adrenal KEYTRUDA, Xb in inhibitor, pembrolizumab, PD-X relacorilant of cortisol. a We the patients with Phase
rarely is patients in These effective form of Pembrolizumab suffer adrenal usually Cushing's and syndrome, lethal cancer quickly the cancer. adrenal effects treating a this combination. of
trial primary full to reducing is killing treat with objective whether patients' by and evaluating can syndrome these achieve reversing cortisol-induced Cushing's immune endpoint of cancer allow rate, overall effect. relacorilant response The including its Our duration by and cortisol excess survival, the response of endpoints progression-free study is secondary survival. pembrolizumab suppression,
known of in shown patients begun with commonly in ALS, placebo-controlled devastating ALS, muscular great double-blind need a for motor is DAZALS, Gehrig's and randomized urgent Dazucorilant trial as and better Phase performance ALS, disease, XXX-patient has an neural modulator and has patients. with dazucorilant illness Lou X atrophy. cortisol enrolling models inflammation our animal selective improving is promise treatment. reducing of
in Europe. collaboration consortium this TRICALS, ALS study conducting with in important are the We academic leading
a of NASH but than expected an oral substantial, large had In I'll and liver transient, to exhibited for to over The and more liver the miricorilant rapid program rarely prior liver of millions study, as States. great demonstrate received who and Miricorilant, rapidly enzymes United in disorder much promise continues fat Finally, NASH. also our NASH, fat, in patients in liver in occurred treatment seen was is of in reductions medication, turn improvement any that patients these our period ALT patients elevations albeit AST. treatment. greater a serious affects we
substantial that doses Xb lower identified a Phase liver has to substantially cause of Our reductions causing irritation. all without than excessive our in study range liver fat appear originally-tested dose-finding doses,
We to this a start Phase expect from to and share study by X results trial midyear later plan year. this
our about of and the development optimistic the patients. our continues of business are business substantial syndrome the of treatment profits to meantime, improve are potential conclusion, generate after making funding significant to even In Cushing's and growth these In screening investments extremely the we programs. all
Our long-held development has of generate that to evidence belief treat a continue potential cortisol the modulation programs validating wide to diseases. our range
substantial relacorilant, also cancer, have others. is will potentially dazucorilant NASH syndrome. Reducing to ALS can straightforward cortisol many attributes. are addition clinical cortisol and benefits effective disorders. cortisol and activity prime Ovarian in modulators offer is modulation different It we a to portfolio for be other many way clear And with -- serious our miricorilant, treat and there and that Cushing's valuable potential in but examples, other
advance Corcept continues across investors employees for fronts. creative I loyal multiple and making thank to our this dedicated possible.
questions. here for stop I'll
